Literature DB >> 24496990

[Invasive breast cancer: the current WHO classification].

A Lebeau1, M Kriegsmann, E Burandt, H-P Sinn.   

Abstract

The World Health Organization (WHO) classification of tumors of the breast defines the international standards for tumor categorization and nomenclature. The fourth edition, published in 2012, provides an update on the current knowledge concerning the classification, immunohistology profile, differential diagnosis and genetics of these lesions. Compared to the previous edition, some terms have been modified, some entities were reclassified and some current molecular data have been added. This article focuses on invasive carcinomas. Definitions for histological diagnosis are supplemented by clinical, macroscopic and molecular characteristics as well as prognostic and predictive features.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24496990     DOI: 10.1007/s00292-013-1841-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  27 in total

Review 1.  An overview of assessment of prognostic and predictive factors in breast cancer needle core biopsy specimens.

Authors:  E A Rakha; I O Ellis
Journal:  J Clin Pathol       Date:  2007-07-14       Impact factor: 3.411

2.  Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases.

Authors:  Sandra J Shin; Paul Peter Rosen
Journal:  Am J Surg Pathol       Date:  2002-04       Impact factor: 6.394

3.  Apocrine mammary carcinoma. A clinicopathologic study of 72 cases.

Authors:  A D Abati; M Kimmel; P P Rosen
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

4.  Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long-term follow-up.

Authors:  S Toikkanen; H Kujari
Journal:  Hum Pathol       Date:  1989-08       Impact factor: 3.466

5.  Neuroendocrine differentiation and prognosis in breast adenocarcinoma.

Authors:  A Miremadi; S E Pinder; A H S Lee; J A Bell; E C Paish; P Wencyk; C W Elston; R I Nicholson; R W Blamey; J F Robertson; I O Ellis
Journal:  Histopathology       Date:  2002-03       Impact factor: 5.087

Review 6.  [Lobular neoplasms and invasive lobular breast cancer].

Authors:  H-P Sinn; B Helmchen; J Heil; S Aulmann
Journal:  Pathologe       Date:  2014-02       Impact factor: 1.011

7.  Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials.

Authors:  Bernhard C Pestalozzi; David Zahrieh; Elizabeth Mallon; Barry A Gusterson; Karen N Price; Richard D Gelber; Stig B Holmberg; Jurij Lindtner; Raymond Snyder; Beat Thürlimann; Elizabeth Murray; Giuseppe Viale; Monica Castiglione-Gertsch; Alan S Coates; Aron Goldhirsch
Journal:  J Clin Oncol       Date:  2008-05-05       Impact factor: 44.544

8.  The changing incidence of in situ and invasive ductal and lobular breast carcinomas: United States, 1999-2004.

Authors:  Christie R Eheman; Kate M Shaw; Aliza Blythe Ryerson; Jacqueline W Miller; Umed A Ajani; Mary C White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05-19       Impact factor: 4.254

9.  Mucinous and neuroendocrine breast carcinomas are transcriptionally distinct from invasive ductal carcinomas of no special type.

Authors:  Britta Weigelt; Felipe C Geyer; Hugo M Horlings; Bas Kreike; Hans Halfwerk; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2009-07-24       Impact factor: 7.842

10.  Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers.

Authors:  Daniel Wetterskog; Maria Angeles Lopez-Garcia; Maryou B Lambros; Roger A'Hern; Felipe C Geyer; Fernanda Milanezi; Maria C Cabral; Rachael Natrajan; Arnaud Gauthier; Kai-Keen Shiu; Nicholas Orr; Sami Shousha; Zoran Gatalica; Alan Mackay; Jose Palacios; Jorge S Reis-Filho; Britta Weigelt
Journal:  J Pathol       Date:  2011-10-20       Impact factor: 7.996

View more
  10 in total

1.  Cluster of differentiation 147 mediates chemoresistance in breast cancer by affecting vacuolar H+-ATPase expression and activity.

Authors:  Yehong Kuang; Shouman Wang; Lili Tang; Jian Hai; Guojiao Yan; Liqiu Liao
Journal:  Oncol Lett       Date:  2018-03-07       Impact factor: 2.967

Review 2.  [Diagnostic imaging of breast cancer : An update].

Authors:  M Funke
Journal:  Radiologe       Date:  2016-10       Impact factor: 0.635

3.  Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.

Authors:  Yangwei Fan; Mengya Li; Ke Ma; Yuan Hu; Jiayu Jing; Yu Shi; Enxiao Li; Danfeng Dong
Journal:  Cancer Biol Ther       Date:  2018-11-21       Impact factor: 4.742

4.  The clinicopathological and MRI features of patients with BRCA1/2 mutations in familial breast cancer.

Authors:  Chao You; Qin Xiao; Xinyi Zhu; Yiqun Sun; Genhong Di; Guangyu Liu; Yifeng Hou; Canming Chen; Jiong Wu; Zhimin Shao; Yajia Gu; Zhen Hu
Journal:  Gland Surg       Date:  2021-01

5.  The volumetric-tumour histogram-based analysis of intravoxel incoherent motion and non-Gaussian diffusion MRI: association with prognostic factors in HER2-positive breast cancer.

Authors:  Chao You; Jianwei Li; Wenxiang Zhi; Yanqiong Chen; Wentao Yang; Yajia Gu; Weijun Peng
Journal:  J Transl Med       Date:  2019-07-02       Impact factor: 5.531

Review 6.  The Potential Role of Hedgehog Signaling in the Luminal/Basal Phenotype of Breast Epithelia and in Breast Cancer Invasion and Metastasis.

Authors:  Arwa Flemban; David Qualtrough
Journal:  Cancers (Basel)       Date:  2015-09-16       Impact factor: 6.639

7.  Expression of CPEB4 in invasive ductal breast carcinoma and its prognostic significance.

Authors:  Hao-Ting Sun; Xin Wen; Tian Han; Zhen-Hua Liu; Shao-Bo Li; Ji-Gang Wang; Xiu-Ping Liu
Journal:  Onco Targets Ther       Date:  2015-11-26       Impact factor: 4.147

8.  Recombinant Dual-target MDM2/MDMX Inhibitor Reverses Doxorubicin Resistance through Activation of the TAB1/TAK1/p38 MAPK Pathway in Wild-type p53 Multidrug-resistant Breast Cancer Cells.

Authors:  Yangwei Fan; Ke Ma; Jiayu Jing; Chuying Wang; Yuan Hu; Yu Shi; Enxiao Li; Qianqian Geng
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

9.  MicroRNA-181d-5p-Containing Exosomes Derived from CAFs Promote EMT by Regulating CDX2/HOXA5 in Breast Cancer.

Authors:  Hongbin Wang; Hong Wei; Jingsong Wang; Lin Li; Anyue Chen; Zhigao Li
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-29       Impact factor: 8.886

10.  Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.

Authors:  Katharina Kriegsmann; Christa Flechtenmacher; Jörg Heil; Jörg Kriegsmann; Gunhild Mechtersheimer; Sebastian Aulmann; Wilko Weichert; Hans-Peter Sinn; Mark Kriegsmann
Journal:  Int J Mol Sci       Date:  2020-09-03       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.